Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine
Clinical trial NCT02621931 · COMPLETED
Trial details
- NCT number
- NCT02621931
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-03-22
- Primary completion
- 2017-04-11
- Enrollment
- 1130
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.